True North Labs

Author: labstruenorth@gmail.com

  • New Clinical Trial Explores Botulinum Toxin for Stroke and Brain Injury-Related Leg Spasticity

    New Clinical Trial Explores Botulinum Toxin for Stroke and Brain Injury-Related Leg Spasticity

    Researchers have launched a clinical trial to evaluate NT 201, a botulinum toxin-based therapy, as a potential treatment for lower limb spasticity resulting from stroke or traumatic brain injury. Spasticity, a common and often painful condition marked by muscle stiffness and involuntary contractions, can significantly limit mobility and quality of life for survivors of these conditions. This study represents an important step toward expanding treatment options for patients navigating long-term recovery.

    The trial is structured as a randomized, placebo-controlled study, considered the gold standard in clinical research. Participants will be randomly assigned to receive either a single 400-unit dose of NT 201 or a placebo, with neither participants nor research staff aware of who receives which treatment. This rigorous design helps ensure that any observed benefits can be attributed to the treatment itself rather than other factors, giving future results strong scientific credibility.

    Following the initial phase, the study includes an open-label extension period in which all participants will receive active treatment for four to five additional cycles, with doses ranging from 400 to 800 units depending on whether spasticity affects only the lower limb or both the upper and lower limbs. This extended phase will allow researchers to gather valuable data on the long-term safety and tolerability of repeated treatments, information that could help shape future dosing guidelines and treatment protocols.

    Botulinum toxin therapies have already shown promise in treating various forms of muscle spasticity, and this trial builds on that foundation by focusing specifically on the needs of stroke and traumatic brain injury survivors. If successful, this research could offer clinicians additional evidence-based options to help patients regain mobility and independence during rehabilitation.

    Trials like this one are essential to advancing the field of neurorehabilitation, offering hope that more effective, well-studied treatments may become available for people managing the aftermath of stroke or brain injury. As the study progresses, its findings will contribute to the broader understanding of how peptide-based and toxin-based therapies can support recovery and improve daily functioning.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury

  • New Phase III Trial to Test Innovative Peptide-Free Chemotherapy Delivery for Peritoneal Cancers

    New Phase III Trial to Test Innovative Peptide-Free Chemotherapy Delivery for Peritoneal Cancers

    Researchers are launching a promising new Phase III clinical trial, known as the IMPACT Trial, to evaluate an innovative treatment approach for patients facing unresectable appendix or colorectal cancer that has spread to the lining of the abdominal cavity, a condition known as peritoneal metastases. This is a particularly challenging diagnosis, and the trial represents a hopeful step toward expanding treatment options for these patients.

    The study will examine Pressurized Intraperitoneal Aerosolized Chemotherapy, or PIPAC, using the drug mitomycin. Unlike traditional chemotherapy infusions delivered through a vein, PIPAC works by delivering chemotherapy as a fine, pressurized mist directly into the abdominal cavity during a minimally invasive laparoscopic procedure. This technique allows the medication to be absorbed more evenly by cancerous tissue while avoiding the need for more invasive open surgery, and it can potentially be repeated multiple times as needed.

    In the trial, patients will receive PIPAC with mitomycin in combination with the standard FOLFIRI chemotherapy regimen, with or without the antiangiogenic drug bevacizumab, and researchers will compare outcomes to those receiving standard FOLFIRI plus bevacizumab alone. The goal is to determine whether this combined, localized-and-systemic approach can offer better results than standard intravenous chemotherapy by itself.

    What makes this approach especially encouraging is its minimally invasive nature and the potential for more targeted, effective delivery of cancer-fighting medication directly where it’s needed most. For patients whose tumors cannot be surgically removed, having additional treatment options that are both innovative and less physically taxing represents meaningful progress in the field of oncology. Trials like IMPACT reflect the ongoing efforts of the medical research community to refine and improve care for people facing difficult-to-treat cancers.

    While it will take time before results are available, the initiation of this Phase III trial marks an important and hopeful development for patients and families affected by appendix and colorectal cancers with peritoneal spread. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial

  • New Clinical Trial Explores Advanced Combination Therapy for Aggressive Lymphoma

    A new clinical trial, known as waveLINE-011, is underway to evaluate innovative treatment combinations for germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL), an aggressive form of blood cancer. The study represents an important step forward in the ongoing effort to identify more effective therapies for patients facing this challenging diagnosis.

    Researchers are comparing two treatment approaches: one combining zilovertamab vedotin (MK-2140) with the established R-CHP regimen (rituximab, cyclophosphamide, doxorubicin, and prednisone), and another using polatuzumab vedotin alongside the same R-CHP backbone. Both zilovertamab vedotin and polatuzumab vedotin belong to a class of medications called antibody-drug conjugates, which are designed to deliver cancer-fighting agents directly to malignant cells while aiming to minimize harm to healthy tissue.

    The primary goal of this study is to determine which combination leads to a greater proportion of patients achieving a complete response, meaning the cancer becomes undetectable following treatment. By directly comparing these two approaches within the GCB DLBCL patient population, researchers hope to gather valuable data that could help refine treatment standards for this specific subtype of lymphoma.

    This type of head-to-head clinical comparison is particularly valuable because it allows the medical community to build a clearer picture of which therapies may offer the most benefit for specific patient populations. GCB DLBCL affects younger, still-maturing B-cells, and studies like this one help researchers understand how best to target this particular disease subtype with increasingly sophisticated treatment options.

    The initiation of this trial reflects the continued momentum in oncology research toward refining and improving combination therapies for blood cancers. As enrollment and data collection progress, the findings from waveLINE-011 could contribute meaningfully to future treatment guidelines for people with this diagnosis. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

  • Oral Cholesterol-Lowering Peptide Wins Approval After Decade-Long Journey

    After roughly a decade of research, development, and clinical testing, an oral peptide designed to help lower cholesterol has received regulatory approval. This marks a significant milestone not just for the specific therapy, but for the broader field of peptide science, which has long grappled with the challenge of making these fragile molecules effective when taken by mouth.

    Peptides are typically broken down by digestive enzymes before they can reach the bloodstream, which is why so many peptide-based treatments have historically required injections. Successfully formulating an oral version that survives the digestive process and still delivers its intended effect represents a genuine engineering and chemistry achievement. This approval suggests that researchers have made real progress in overcoming that long-standing hurdle.

    For patients managing cholesterol, an oral option could mean a more convenient, less invasive way to support cardiovascular health. Needle-free treatments tend to be easier to incorporate into daily routines, which may help more people stay consistent with their prescribed regimens over time. Consistency matters a great deal when it comes to managing long-term conditions like high cholesterol, so improving the ease of use could have meaningful downstream benefits for patient outcomes.

    This development also serves as an encouraging signal for the peptide therapeutics field more broadly. The techniques and insights gained from a decade of formulation work on this particular oral peptide may pave the way for other peptide-based treatments to make the same leap from injectable to oral delivery. That could open doors for a wider range of conditions to be treated with peptide therapies that are simpler for patients to access and use.

    The approval stands as a reminder that meaningful medical advances often take patience and sustained effort. A decade of refinement, testing, and regulatory review has now resulted in a new tool that clinicians and patients may be able to turn to for cardiovascular support. As with any new therapy, individuals should talk with their healthcare provider to understand whether it might be appropriate for their specific situation.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Oral cholesterol-lowering peptide approved after a decade in development – Chemistry World

  • Ascletis Advances Two Novel Obesity Peptide Candidates with FDA IND Submissions

    Ascletis has taken an important step forward in the development of next-generation obesity treatments by submitting two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration. The filings mark the beginning of the regulatory pathway that could bring two promising peptide-based therapies closer to clinical testing in the United States.

    The first candidate, ASC36, is a once-monthly injectable peptide that acts as an amylin receptor agonist. Amylin receptor agonists represent a growing area of interest in obesity research, as they work through pathways that can complement or extend the effects of other metabolic therapies. The convenience of a once-monthly dosing schedule, if supported by future trial data, could offer patients a more manageable treatment option compared to more frequent injection regimens.

    The second application covers ASC36_35, a fixed-dose combination (FDC) that pairs ASC36 with a peptide GLP-1R/GIPR agonist, also formulated for once-monthly administration. Combination approaches that engage multiple metabolic receptor pathways have become a major focus in obesity drug development, with the goal of potentially improving efficacy while simplifying treatment regimens for patients managing weight-related health conditions.

    The submission of these IND applications is a meaningful milestone, as it reflects the progress Ascletis has made in preclinical development and sets the stage for the company to seek clearance to begin human clinical trials in the U.S. If cleared, these programs would join a broader wave of innovation in the peptide therapeutics space, where researchers continue to explore new ways to help patients achieve sustainable, long-term weight management with less frequent dosing.

    Once-monthly injectable options, if proven safe and effective through the clinical trial process, could represent a significant convenience improvement for patients who currently rely on weekly injections. As with all early-stage drug candidates, these therapies will need to progress through rigorous clinical evaluation before any conclusions about safety or effectiveness can be drawn. True North Labs will continue to follow this story as it develops.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agon – PR Newswire

  • FDA Advisory Panel Vote Signals Broader Access to Popular Peptides

    FDA Advisory Panel Vote Signals Broader Access to Popular Peptides

    An FDA advisory panel has cast a vote that could pave the way for broader access to some of the most talked-about peptide compounds on the market today. While the final regulatory decision still rests with the FDA itself, panel votes like this often signal a meaningful shift in how the agency views the safety and accessibility of a given category of treatments.

    For years, many peptides have existed in a regulatory gray area, available primarily through compounding pharmacies or specialized clinics, which can create hurdles for patients seeking these therapies. A favorable panel vote suggests growing confidence among experts that certain peptides may be appropriate for wider distribution, potentially simplifying the path for patients and providers alike.

    This development is being welcomed by many in the wellness and longevity communities, where peptides have gained popularity for their potential roles in areas like metabolic health, recovery, and healthy aging. Easier access could mean more consistent product quality, better oversight, and reduced costs for consumers who currently navigate a patchwork of sourcing options.

    It’s important to note that a panel vote is not the same as final FDA approval or a formal policy change—those steps typically follow additional review. Still, this kind of movement within the regulatory process is often viewed as an encouraging sign for a category of compounds that has drawn increasing scientific and public interest in recent years.

    As always, developments like this underscore the importance of working with qualified healthcare providers to understand what any regulatory changes might mean for individual treatment options. This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Millions could gain easier access to popular peptides after FDA panel vote – Fox News

  • Nuritas’ PeptiSleep Peptide Shows Promise for Better Sleep and Heart Rate Variability

    Nuritas’ PeptiSleep Peptide Shows Promise for Better Sleep and Heart Rate Variability

    Biotechnology company Nuritas has announced encouraging results for its PeptiSleep ingredient, a bioactive peptide identified through the company’s AI-powered discovery platform. According to reporting from Nutraceutical Business Review, the peptide has shown the ability to support improved sleep quality alongside favorable changes in heart rate variability (HRV), a key marker often associated with better recovery and overall autonomic nervous system balance.

    Sleep support is one of the fastest-growing areas of interest in the wellness and nutraceutical space, with many consumers seeking natural alternatives to conventional sleep aids. Peptides like PeptiSleep represent a growing category of bioactive compounds derived from natural sources and refined using advanced computational tools to identify molecules with targeted physiological effects. Nuritas has built its reputation on using artificial intelligence to scan vast libraries of naturally occurring peptides, aiming to uncover ingredients with meaningful health benefits.

    The connection between sleep quality and HRV is notable because HRV is frequently used as an indicator of how well the body manages stress and recovers during rest. Improvements in this measure, paired with subjective or objective gains in sleep quality, suggest that PeptiSleep may be influencing the body’s relaxation and recovery processes in a beneficial way. This kind of dual benefit could be appealing to companies formulating supplements aimed at stress relief, recovery, and nighttime wellness.

    For the nutraceutical industry, findings like these highlight the continued momentum behind peptide-based ingredients as functional additions to sleep and wellness products. As interest in natural, science-backed solutions for sleep continues to rise, ingredients supported by real-world data may find growing traction among formulators and consumers alike. Nuritas’ work also reflects a broader trend of using AI to accelerate the discovery of novel peptides with specific, targeted benefits rather than relying solely on traditional trial-and-error methods.

    While these results are promising, further peer-reviewed research and larger-scale studies will help clarify the full scope of PeptiSleep’s benefits and how it might best be used within sleep-support formulations. As always, this article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Nuritas’ PeptiSleep shows improved sleep quality and HRV – Nutraceutical Business Review

  • Silk-Derived Peptide Platform Powers New FDA-Cleared Therapy for Atopic Dermatitis

    Evolved By Nature, a biotechnology company known for its peptide-based innovations, has announced that its proprietary peptide platform is now part of a newly FDA-cleared prescription therapy aimed at helping patients manage atopic dermatitis, a chronic and often uncomfortable skin condition affecting millions of people worldwide. This clearance marks an encouraging step forward in bringing peptide-based science into everyday dermatological care.

    Atopic dermatitis, commonly known as eczema, causes inflammation, itching, and dryness that can significantly affect quality of life. Many patients seek treatments that not only relieve symptoms but also support the skin’s natural barrier function. Evolved By Nature’s platform is built around bioengineered peptides inspired by natural silk protein structures, which the company has spent years refining for use in skincare and therapeutic applications. Their integration into an FDA-cleared product suggests that peptide technology is increasingly viewed as both safe and effective for regulatory approval in skin health treatments.

    What makes this development particularly promising is the broader signal it sends about the maturation of peptide science within the biotech and pharmaceutical space. FDA clearance for a prescription therapy indicates that the product has met required standards for safety and manufacturing quality, giving patients and healthcare providers a new evidence-based option to consider when addressing atopic dermatitis symptoms.

    For the peptide research community, this milestone reflects the expanding real-world applications of peptide platforms beyond injectables and supplements, into targeted topical therapies. It also underscores how biomaterials inspired by nature, such as silk-derived proteins, can be translated into modern medical solutions through careful engineering and clinical validation. As more companies explore similar peptide-based innovations, patients dealing with chronic skin conditions may benefit from an increasing range of scientifically-backed treatment options in the future.

    This is an encouraging example of how peptide technology continues to move from laboratory research into practical, regulator-approved solutions that could improve everyday health and comfort. As always, patients should consult with their healthcare provider to determine whether any new therapy is appropriate for their individual needs. This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Evolved By Nature’s Peptide Platform Used in FDA-Cleared Prescription Therapy for the Management of Atopic Dermatitis – PR Newswire

  • FDA Advisory Committee Votes to Expand Access to Peptide Therapies

    FDA Advisory Committee Votes to Expand Access to Peptide Therapies

    In a development that could reshape the landscape for peptide-based medicine, a Food and Drug Administration advisory committee has voted to support making certain peptides more widely available. While FDA advisory committee recommendations are not binding, they carry significant weight in shaping the agency’s future decisions and often signal a shift toward more accessible treatment options for patients and practitioners alike.

    Peptides, short chains of amino acids that play a role in everything from hormone regulation to tissue repair, have generated growing interest across the medical and wellness communities in recent years. Many of these compounds have historically existed in a regulatory gray area, with limited pathways for legitimate access outside of compounding pharmacies or research settings. A vote in favor of expanded availability suggests that regulators are increasingly recognizing the therapeutic potential of this class of molecules and are willing to consider frameworks that could make them easier to obtain through appropriate medical channels.

    For the peptide research and clinical community, this news is an encouraging sign. Expanded access, if it materializes through formal FDA policy, could mean more patients benefiting from peptide therapies under proper medical supervision, more opportunities for manufacturers to pursue quality-assured production, and potentially more resources directed toward further clinical study. It also reflects a broader trend of regulatory bodies taking a closer, more constructive look at peptides as legitimate therapeutic tools rather than niche or unregulated substances.

    It’s worth noting that a committee vote is just one step in a longer regulatory process. The FDA will need to weigh the recommendation carefully, and any resulting policy changes would likely come with appropriate safeguards, quality standards, and oversight to ensure patient safety. Still, this vote represents meaningful forward momentum for a field that has long sought clearer, more supportive regulatory pathways.

    True North Labs will continue to monitor how this recommendation develops and what it could mean for the future of peptide access and research. As always, we’re encouraged to see thoughtful regulatory engagement that could ultimately benefit patients and the broader scientific community.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: FDA committee votes to make peptides more widely available – Science | AAAS

  • Promising ‘Triple-Agonist’ Weight Loss Peptide Reaching Some Patients Ahead of Full Approval

    Excitement is building around a new class of metabolic therapies often nicknamed “Triple G” drugs because they act on three key hormone pathways at once — GLP-1, GIP, and glucagon. Unlike earlier single- or dual-target medications, this triple-action approach is designed to more comprehensively address appetite regulation, blood sugar control, and energy expenditure, and early clinical trial data have shown notably strong results for weight reduction.

    According to recent reporting, a limited number of patients may be able to access this investigational treatment through expanded-access or early-access programs even before the drug completes the full FDA approval process. Expanded access pathways are typically reserved for therapies that have already demonstrated meaningful safety and efficacy signals in trials, and their use here reflects growing confidence in the drug’s potential benefit for patients dealing with obesity and related metabolic conditions.

    For the broader peptide and metabolic health community, this development is a signal of how quickly innovation in this space is moving. Triple-hormone agonists represent a scientific evolution beyond the GLP-1 drugs that have already reshaped weight management in recent years, and if trial results continue to hold up, they could offer an even more effective option for people who have struggled to reach their health goals with existing therapies.

    It’s also encouraging to see regulatory flexibility being used thoughtfully — allowing appropriate patients earlier access to promising treatments while the full approval and safety review process continues in parallel. This kind of balanced approach can help bridge the gap between exciting trial data and the years-long timeline typically required for full market authorization.

    As with any emerging therapy, full FDA approval will depend on continued trial data confirming both safety and long-term effectiveness. Patients and providers should look forward to official guidance as this treatment moves through the remaining stages of review.

    This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Some patients to score new super-effective ‘Triple G’ weight loss drug — before FDA approval – New York Post